Company intelligence / Profile preview

Guangzhou Saijun Biotechnology Co., Ltd.

Guangzhou, Guangdong, Chinacellgenes.com ↗

Ownership: Private
Development stage: Other

Overview

Guangzhou Saijun Biotechnology develops allogeneic human bone marrow-derived mesenchymal stem cell therapies. Its lead product "CG-BM1" has received clinical implied approval in China for treating moderate/severe adult ARDS caused by infection since at least 2021. In December 2022, the company filed an IND application for a new indication—chronic and acute liver failure—which was accepted by Chinese regulators. The company appears focused on advancing its MSC-based therapies through clinical development targeting severe inflammatory and organ failure conditions.

Therapeutic areas: GastroenterologyPulmonology
Modalities: Allogeneic mesenchymal stem cells (MSCs)Cell therapy
Industry: Biotech

Drug pipeline

3 assets

CG-BM1

2 more assets in the full pipeline.

Beyond the preview

Go deeper on Guangzhou Saijun Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangzhou Saijun Biotechnology Co., Ltd..